Tyco's split raises queries on Bard deal
This article was originally published in Clinica
Tyco International's unexpected plan to split into four businesses has complicated its proposed $3.1 billion merger with CR Bard. As a result of the split, Tyco's healthcare business, the second largest medtech company worldwide after Johnson & Johnson, will become an independent, "pure play" company.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.